Flatlander schreef op 21 okt 2019 om 05:00:
I miss a lot in the translation of the previous messages but I'd like to add my perspective of why I have jumped a lot of hurdles to invest in BCART. I see BCRT as being situated at the intersection of personalized medicine and automation. Like Apple, BCART is heavily dependent on its development partners. My belief is that one of them will launch a Killer Ap that will drive idylla console and cartridge sales. I think OncoDX Breast and Seticyte are strong candidates.
I can agree with DZR that a high percentage of biotechs fail. But the rate of failure decreases with the number of product launches. BCART is pushing 10 products, with numerous others in development. Under these circumstances the potential for failure is greatly reduced.